Wedbush raised its price target on shares of Anacor Pharmaceuticals Inc. (ANAC) Friday morning to $20 from $10. Anacor reported positive results from a Phase 2 dose-ranging trial of its topical boron-based phosphodiesterase-4 inhibitor, AN2728 on Thursday.
Anacor Pharmaceuticals gapped up Friday and climbed in early trade, but settled into a range for the majority of the session. Shares closed up by 1.24 at $6.08 on the highest volume of the year. The stock rose to a 5-month high and re-crossed its 200-day moving average.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.